Aktie A3C2HG CLARUS THERAPEUTICS HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Clarus Therapeutics Holdings, Inc.

Aktien

A3C2HG

US18271L1070

CRXT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Clarus Therapeutics Holdings, Inc. Went Out of Business
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer
Clarus Therapeutics Holdings, Inc. Announces Executive Changes
Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc.
Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. Filed for Bankruptcy
CLARUS THERAPEUTICS HOLDINGS, INC. : Needham & Co. passe à neutre sur le dossier
CLARUS THERAPEUTICS HOLDINGS, INC. : Maxim abaisse son opinion à neutre
Sector Update: Health Care Stocks a Rare Positive in Friday Trading
Clarus Therapeutics Holdings Inc Contemplates Bankruptcy
Clarus Therapeutics Posts Higher Revenue in Q2; Planned 40% Workforce Cut to be Completed in August
Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022
Clarus Therapeutics Posts Higher Revenue in Q2
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Clarus Therapeutics Holdings, Inc. Announces Reduction in Workforce by Approximately 40% of Total Headcount
Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees
Oragenics Appoints Kimberly Murphy as President, CEO
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C2HG Aktie
  4. Nachrichten Clarus Therapeutics Holdings, Inc.
  5. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT